This technique was initially developed for treatment of neuroendocrine tumours [30] and has been used more recently in prostate cancer, as demonstrated in the TheraP [11] and VISION [12] trials showing that 177Lu-PSMA improved progression-free and overall survival; thus, it is now utilised in the treatment of metastatic castrate-resistant prostate cancer. Here, FOLH1 is linked to prostate cancer.